GPCR Structure Therapeutics Inc.
Nasdaq · SEC CIK 1888886 · EDGAR
- Bought, last 12 months
- $0 0 purchases by 0 insiders
- Sold, last 12 months
- $0 0 sales by 0 insiders
- Filings on record
- 92 since 2023-02-06, latest 2026-09-22 17:59
BoughtSold
Most active insiders, 12 months
| Insider | Title | Bought | Sold |
|---|---|---|---|
| Berrios John Joseph | Chief Commercial Off | — | — |
| Coll Crespo Blas | Chief MEDICAL Off | — | — |
| Ma Yingli | CTO | — | — |
| Lin Xichen | CSO | — | — |
| Yoon Jun | CFO | — | — |
| Hall Ashley | Chief Development Off | — | — |
| Lang Matthew | COO, GC | — | — |
| Stevens Raymond C | CEO, Dir | — | — |
Transactions 62
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-09-22 17:59 | 2026-09-18 | GPCR | Coll Crespo Blas | Chief MEDICAL Off | F - Tax | $11.67 | -10.6K | 270.3K | -4% | -$124.0K |
| DT | 2026-09-22 17:59 | 2026-09-21 | GPCR | Coll Crespo Blas | Chief MEDICAL Off | C - Cnv Deriv | $0.00 | -12.0K | 258.2K | -4% | $0 |
| DT | 2026-09-02 21:18 | 2026-09-01 | GPCR | Lin Xichen | CSO | M - OptEx | $0.34 | +17.8K | 246.8K | +8% | +$6,058 |
| DT | 2026-09-02 21:18 | 2026-09-01 | GPCR | Lin Xichen | CSO | C - Cnv Deriv | $0.00 | -17.8K | 229.0K | -7% | $0 |
| DT | 2026-08-19 20:23 | 2026-08-18 | GPCR | Lin Xichen | CSO | M - OptEx | $0.34 | +11.8K | 240.8K | +5% | +$4,018 |
| DT | 2026-08-19 20:23 | 2026-08-18 | GPCR | Lin Xichen | CSO | C - Cnv Deriv | $0.00 | -11.8K | 229.0K | -5% | $0 |
| D | 2026-08-07 16:08 | 2026-08-06 | GPCR | Berrios John Joseph | Chief Commercial Off | A - Grant | $0.00 | +140.8K | 140.8K | New | $0 |
| DT | 2026-08-05 16:49 | 2026-08-04 | GPCR | Lin Xichen | CSO | M - OptEx | $0.34 | +11.8K | 240.8K | +5% | +$4,018 |
| DT | 2026-08-05 16:49 | 2026-08-04 | GPCR | Lin Xichen | CSO | C - Cnv Deriv | $0.00 | -11.8K | 229.0K | -5% | $0 |
| DT | 2026-07-15 18:57 | 2026-07-14 | GPCR | Lin Xichen | CSO | M - OptEx | $0.34 | +23.6K | 252.6K | +10% | +$8,036 |
| DT | 2026-07-15 18:57 | 2026-07-14 | GPCR | Lin Xichen | CSO | C - Cnv Deriv | $0.00 | -23.6K | 229.0K | -9% | $0 |
| DT | 2026-06-29 20:32 | 2026-06-25 | GPCR | Lin Xichen | CSO | M - OptEx | $0.34 | +23.6K | 252.6K | +10% | +$8,036 |
| DT | 2026-06-29 20:32 | 2026-06-25 | GPCR | Lin Xichen | CSO | C - Cnv Deriv | $0.00 | -23.6K | 229.0K | -9% | $0 |
| D | 2026-04-23 16:21 | 2026-04-15 | GPCR | Lang Matthew | COO, GC | A - Grant | $0.00 | +184.6K | 184.6K | New | $0 |
| D | 2026-03-23 | 2026-03-19 | GPCR | Yoon Jun | CFO | A - Grant | $0.00 | +104.1K | 1.40M | +8% | $0 |
| D | 2026-03-23 | 2026-03-19 | GPCR | Hall Ashley | Chief Development Off | A - Grant | $0.00 | +47.7K | 155.2K | +44% | $0 |
| D | 2026-03-23 | 2026-03-19 | GPCR | Coll Crespo Blas | Chief MEDICAL Off | A - Grant | $0.00 | +75.9K | 280.9K | +37% | $0 |
| D | 2026-03-23 | 2026-03-19 | GPCR | Stevens Raymond C | CEO, Dir | A - Grant | $0.00 | +260.2K | 1.40M | +23% | $0 |
| D | 2026-03-23 | 2026-03-19 | GPCR | Lin Xichen | CSO | A - Grant | $0.00 | +43.4K | 229.0K | +23% | $0 |
| D | 2026-03-23 | 2026-03-19 | GPCR | Ma Yingli | CTO | A - Grant | $0.00 | +32.5K | 139.9K | +30% | $0 |
| 2026-03-05 | 2026-03-03 | GPCR | Ma Yingli | CTO | F - Tax | $20.99 | -11.3K | 107.4K | -10% | -$237.5K | |
| D | 2026-03-05 | 2026-03-03 | GPCR | Hall Ashley | Chief Development Off | F - Tax | $20.99 | -4,836 | 107.5K | -4% | -$101.5K |
| 2026-03-05 | 2026-03-03 | GPCR | Coll Crespo Blas | Chief MEDICAL Off | F - Tax | $20.99 | -11.8K | 205.0K | -5% | -$248.2K | |
| 2026-03-05 | 2026-03-03 | GPCR | Yoon Jun | CFO | F - Tax | $20.99 | -22.3K | 1.30M | -2% | -$468.2K | |
| 2026-03-05 | 2026-03-03 | GPCR | Lin Xichen | CSO | F - Tax | $20.99 | -18.7K | 185.6K | -9% | -$393.2K | |
| D | 2026-03-05 | 2026-03-03 | GPCR | Stevens Raymond C | CEO, Dir | F - Tax | $20.99 | -53.5K | 1.14M | -4% | -$1.12M |
| 2025-09-22 | 2025-09-18 | GPCR | Hall Ashley | Chief Development Off | F - Tax | $7.74 | -6,021 | 112.3K | -5% | -$46.6K | |
| 2025-09-22 | 2025-09-18 | GPCR | Coll Crespo Blas | Chief MEDICAL Off | F - Tax | $7.74 | -8,106 | 216.8K | -4% | -$62.7K | |
| 2025-08-20 | 2025-07-01 | GPCR | Lin Xichen | CSO | F - Tax | $6.84 | -12.8K | 204.3K | -6% | -$87.9K | |
| 2025-08-20 | 2025-07-01 | GPCR | Ma Yingli | CTO | F - Tax | $6.84 | -4,470 | 118.7K | -4% | -$30.6K | |
| D | 2025-07-03 | 2025-07-01 | GPCR | Yoon Jun | CFO | A - Grant | $0.00 | +39.6K | 1.33M | +3% | $0 |
| DM | 2025-07-03 | 2025-03-01+ | GPCR | Yoon Jun | CFO | F - Tax | $7.33 | -13.0K | 1.29M | -1% | -$95.5K |
| DM | 2025-07-03 | 2025-03-01+ | GPCR | Stevens Raymond C | CEO, Dir | F - Tax | $7.31 | -28.5K | 1.12M | -2% | -$208.7K |
| D | 2025-07-03 | 2025-07-01 | GPCR | Stevens Raymond C | CEO, Dir | A - Grant | $0.00 | +89.7K | 1.21M | +8% | $0 |
| 2025-07-03 | 2025-07-01 | GPCR | Lin Xichen | CSO | A - Grant | $0.00 | +57.1K | 217.2K | +36% | $0 | |
| 2025-07-03 | 2025-03-01 | GPCR | Lin Xichen | CSO | F - Tax | $7.92 | -6,441 | 160.1K | -4% | -$51.0K | |
| D | 2025-07-03 | 2025-07-01 | GPCR | Coll Crespo Blas | Chief MEDICAL Off | A - Grant | $0.00 | +7,992 | 226.3K | +4% | $0 |
| DM | 2025-07-03 | 2025-03-01+ | GPCR | Coll Crespo Blas | Chief MEDICAL Off | F - Tax | $7.34 | -2,667 | 218.4K | -1% | -$19.6K |
| 2025-07-03 | 2025-03-01 | GPCR | Ma Yingli | CTO | F - Tax | $7.92 | -1,824 | 98.7K | -2% | -$14.4K | |
| 2025-07-03 | 2025-07-01 | GPCR | Ma Yingli | CTO | A - Grant | $0.00 | +24.5K | 123.2K | +25% | $0 | |
| D | 2025-03-18 | 2025-03-15 | GPCR | Yoon Jun | CFO | A - Grant | $0.00 | +170.2K | 1.29M | +15% | $0 |
| D | 2025-03-18 | 2025-03-15 | GPCR | Lin Xichen | CSO | A - Grant | $0.00 | +80.8K | 166.5K | +94% | $0 |
| D | 2025-03-18 | 2025-03-15 | GPCR | Coll Crespo Blas | Chief Medical Off | A - Grant | $0.00 | +117.0K | 219.6K | +114% | $0 |
| D | 2025-03-18 | 2025-03-15 | GPCR | Ma Yingli | CTO | A - Grant | $0.00 | +63.8K | 100.5K | +174% | $0 |
| D | 2025-03-18 | 2025-03-15 | GPCR | Stevens Raymond C | CEO, Dir | A - Grant | $0.00 | +340.3K | 1.13M | +43% | $0 |
| D | 2025-03-18 | 2025-03-15 | GPCR | Hall Ashley | Chief Development Off | A - Grant | $0.00 | +51.0K | 118.3K | +76% | $0 |
| D | 2024-09-20 | 2024-09-18 | GPCR | Hall Ashley | Chief Development Off | A - Grant | $0.00 | +67.3K | 67.3K | New | $0 |
| D | 2024-09-20 | 2024-09-18 | GPCR | Coll Crespo Blas | Chief Medical Off | A - Grant | $0.00 | +90.6K | 102.6K | +755% | $0 |
| DM | 2024-06-14 | 2024-06-12 | GPCR | Stevens Raymond C | CEO, Dir | M - OptEx | $0.42 | +150.0K | 743.3K | +25% | +$63.0K |
| D | 2024-06-12 | 2024-06-10 | GPCR | Stevens Raymond C | CEO, Dir | C - Cnv Deriv | $0.00 | -555.0K | 643.3K | -46% | $0 |
| D | 2024-06-05 | 2024-06-03 | GPCR | Lin Xichen | CSO | M - OptEx | $0.34 | +106.2K | 191.9K | +124% | +$36.1K |
| D | 2024-06-05 | 2024-06-03 | GPCR | Lin Xichen | CSO | C - Cnv Deriv | $0.00 | -106.2K | 85.7K | -55% | $0 |
| D | 2024-03-19 | 2024-03-15 | GPCR | Ma Yingli | CTO | A - Grant | $0.00 | +36.7K | 36.7K | New | $0 |
| D | 2024-03-19 | 2024-03-15 | GPCR | Yoon Jun | CFO | A - Grant | $0.00 | +59.5K | 1.12M | +6% | $0 |
| D | 2024-03-19 | 2024-03-15 | GPCR | Lin Xichen | CSO | A - Grant | $0.00 | +85.7K | 85.7K | New | $0 |
| D | 2024-03-19 | 2024-03-15 | GPCR | Stevens Raymond C | CEO, Dir | A - Grant | $0.00 | +134.7K | 1.20M | +13% | $0 |
| D | 2024-03-19 | 2024-03-15 | GPCR | Bach Mark Allen | Chief MEDICAL Off | A - Grant | $0.00 | +26.2K | 26.2K | New | $0 |
| DM | 2023-05-12 | 2023-05-10 | GPCR | BIOTECHNOLOGY VALUE FUND L P | See explanation of responses | J - Other | — | -7.41M | 0 | -100% | — |
| DI | 2023-02-09 | 2023-02-07 | GPCR | Farid Ramy | Dir | C - Cnv Deriv | — | +642.2K | 3.26M | +25% | — |
| DMI | 2023-02-09 | 2023-02-07 | GPCR | FIL Ltd | See Remark 1 | C - Cnv Deriv | — | +6.47M | 494.0K | New | — |
| DMI | 2023-02-09 | 2023-02-07 | GPCR | FMR LLC | See Remark 1 | C - Cnv Deriv | — | +5.82M | 57.5K | New | — |
| DI | 2023-02-09 | 2023-02-07 | GPCR | WELCH DANIEL G | Dir | C - Cnv Deriv | — | +123.5K | 123.5K | New | — |
Purchase Sale Sale after option exercise All abbreviations